Selected Posters and Abstracts
Nelfinavir (Viracept) [PI]
[P172] Why do patients continue on a non-boosted PI regimen? Data from a cohort of 1012 nelfinavir (NFV)-treated patients
A Antela and others.
[P173] Patient perception about NFV-containing therapy: results in a cohort of 1012 patients from Spain
A Antela and others.
[P297] Influence of highly active antiretroviral therapy with nelfinavir on endothelial cell-derived microparticles in human immunodeficiency virus-1-infected patients
Oleksii M Korzh and others.
[P96] Role of circulating thrombomodulin level in latent progression of atherosclerosis in human immunodeficiency virus-1-infected patients receiving highly active antiretroviral therapy with nelfinavir
Iryna Korzh and others.
[P364] 5-year outcome in 19 HIV1-positive children treated with 2 nucleoside reverse transcriptase inhibitors + nelfinavir as first line protease inhibitor
Bernd Buchholz and others.


<— Conference Main Page

Conference
Main Page


FDA-Approved
HIV and AIDS Treatments

Protease Inhibitors
Agenerase
Aptivus
Crixivan
Fortovase
Invirase
Kaletra
Lexiva

Norvir
Prezista

Reyataz
Viracept


Nucleoside / Nucleotide Reverse Transcriptase Inhibitors

Combivir
Epivir
Emtriva
Epzicom
Hivid
Retrovir
Trizivir
Truvada  
Videx
Viread
Zerit
Ziagen


non Nucleoside Reverse Transcriptase Inhibitors
Rescriptor

Sustiva
Viramune

Entry Inhibitors
Fuzeon

Fixed-dose Combinations
Atripla
Combivir
Trizivir
Truvada